TSW
SLXP

Thompson Siegel & Walmsley’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Thompson Siegel & Walmsley’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-266,916
Closed -$17.7M – 698
2013
Q2 		$17.7M Buy
+266,916
New +$15.3M 0.38% 108

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Thompson Siegel & Walmsley's SLXP Position: Q3 2013 in Review

Thompson Siegel & Walmsley sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2013, closing a stake of 266,916 shares — an estimated $17.7M sold.

Thompson Siegel & Walmsley first reported a position in SLXP in Q2 2013 and held it in 1 quarter. The position peaked at $17.7M in Q2 2013. 251 funds tracked by Wall St. Rank hold SLXP as of Q3 2013.

  • Thompson Siegel & Walmsley reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2013 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 266,916 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2013, an estimated $17.7M.
  • Thompson Siegel & Walmsley first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's SALIX PHARMACEUTICALS LTD DEL position peaked at $17.7M in Q2 2013.
  • 251 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2013.

Based on Thompson Siegel & Walmsley's 13F filing for Q3 2013, filed 12 Nov 2013.